Targeting the USP14/Anillin Axis Enhances Radiosensitivity by Inactivating the Wnt/β- Catenin Pathway in Esophageal Squamous Carcinoma

Esophageal cancer is a formidable disease, particularly in its advanced stages when the tube connecting the throat to the stomach becomes blocked, making it difficult or impossible to swallow. For patients who cannot undergo surgery, doctors often turn to a treatment called brachytherapy. This involves placing a stent loaded with tiny radioactive seeds directly into the blockage. These seeds emit a steady, low dose of radiation over time to shrink the tumor and keep the passage open. While this approach offers relief, it does not work for everyone. A significant portion of patients find that their tumors do not respond well to the radiation, or they stop responding after a while, leading to the cancer returning. The reason for this resistance has remained a mystery, but understanding it is the key to helping more people survive.

At the heart of this mystery lies a complex system inside our cells that decides which proteins to keep and which to destroy. Imagine a cell as a busy factory where proteins are the workers. To keep the factory running smoothly, the cell constantly tags workers that are damaged or no longer needed with a small molecular tag called ubiquitin. This tag acts like a "destroy" signal, sending the protein to a cellular recycling center called the proteasome to be broken down. However, there are also enzymes that can remove these tags, effectively saving the protein from destruction. When this system goes wrong, dangerous proteins can build up and help cancer cells grow or resist treatment. Scientists have long suspected that a specific protein called Anillin, which helps cells divide, might be involved in this process, but its exact role in radiation resistance was unclear.

In a new study, researchers set out to uncover how Anillin influences the success of brachytherapy in esophageal squamous cell carcinoma, the most common type of esophageal cancer in Asia. They began by looking at tissue samples from patients who had received radioactive stents. They found that in patients whose tumors did not respond well to the radiation, the levels of Anillin were unusually high. To test if this protein was actually causing the resistance, the team turned to laboratory experiments. They took esophageal cancer cells that were known to be resistant to radiation and used genetic tools to reduce the amount of Anillin inside them. When they exposed these modified cells to the same radiation dose used in patients, the cells with low Anillin levels died much more easily than the unmodified ones. They formed fewer colonies, showed more signs of DNA damage, and were far less able to spread to other areas. This suggested that Anillin was acting as a shield, protecting the cancer cells from the radiation.

The researchers then dug deeper to understand how this shield worked. They discovered that Anillin does not act alone; it functions as a scaffold, a structural platform that brings other proteins together. Specifically, they found that Anillin recruits an enzyme called USP14. This enzyme acts as a tag-remover, capable of stripping the "destroy" signals off other proteins. In this case, Anillin brings USP14 close to a protein called beta-catenin. Normally, beta-catenin is tagged for destruction, but when Anillin and USP14 team up, they remove the tags, allowing beta-catenin to accumulate and survive. High levels of beta-catenin activate a signaling pathway known as Wnt, which tells the cell to grow and repair itself. By keeping beta-catenin safe, Anillin essentially turns on a survival switch that helps the cancer cells repair the damage caused by the radiation and continue to thrive.

To confirm this chain of events, the scientists performed a series of rigorous tests. They showed that when they blocked Anillin, the beta-catenin protein was no longer protected; it was tagged for destruction and broken down by the cell's recycling system. They also demonstrated that the interaction between Anillin and USP14 was direct and physical. In experiments using computer modeling, they visualized how these proteins fit together, calculating the strength of their bond to ensure the connection was plausible. Furthermore, they tested whether reactivating the survival pathway could undo the benefits of removing Anillin. When they used a chemical to artificially boost the Wnt pathway in cells where Anillin had been removed, the cells regained their resistance to radiation. This proved that the entire mechanism hinges on this specific pathway: Anillin recruits USP14 to save beta-catenin, which in turn drives the resistance.

The study also looked at what happens inside living animals to see if these findings held up in a more complex environment. The team implanted human esophageal cancer cells into mice and treated them with brachytherapy seeds similar to those used in humans. Mice with tumors that had normal levels of Anillin showed only modest improvement after treatment. However, in mice where the researchers had genetically reduced Anillin levels, the tumors shrank significantly more, and the spread of cancer to the lungs was greatly reduced. The combination of lowering Anillin and applying radiation was far more effective than radiation alone, without causing additional harm to the mice. These results confirmed that targeting Anillin could make the radiation therapy much more potent.

This work provides a clear explanation for why some esophageal cancers resist brachytherapy and points toward a new way to treat them. The researchers found that Anillin acts as a master organizer, gathering the tools needed to protect a key survival protein from being destroyed. By disrupting this partnership, it is possible to strip away the cancer's defenses and make it vulnerable to radiation again. While this study was conducted in the lab and in animal models, the findings offer a promising direction for future treatments. If doctors can develop drugs to block the interaction between Anillin and USP14, they might be able to turn the tide for patients who currently do not respond to standard radiation therapy, offering a new hope for overcoming one of the most stubborn forms of esophageal cancer.